Compare SHEN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | DRUG |
|---|---|---|
| Founded | 1902 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Pharmaceuticals and Biotechnology |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.1M | 744.9M |
| IPO Year | 1994 | 2020 |
| Metric | SHEN | DRUG |
|---|---|---|
| Price | $11.22 | $74.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $26.00 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 461.8K | 257.8K |
| Earning Date | 05-01-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $357,854,000.00 | N/A |
| Revenue This Year | $7.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $9.67 | $25.77 |
| 52 Week High | $17.35 | $123.75 |
| Indicator | SHEN | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 21.91 | 54.33 |
| Support Level | $10.85 | $72.18 |
| Resistance Level | $11.24 | $74.92 |
| Average True Range (ATR) | 0.65 | 5.41 |
| MACD | -0.18 | 1.04 |
| Stochastic Oscillator | 0.44 | 69.86 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.